KALA BIO, INC. Proceeds from (Repayments of) Secured Debt
KALA BIO, INC. (KALA) reported Proceeds from (Repayments of) Secured Debt of $2.73 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-02-12.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepaymentsOfSecuredDebt · last filed 2020-02-12
- KALA BIO, INC. proceeds from (repayments of) secured debt for fiscal 2018 was $2.73M.
| Period end | Proceeds from (Repayments of) Secured Debt 12 month |
|---|---|
| 2018-12-31 | $2.73M 10-K · filed 2020-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |